UVD Robots Deploys Largest Fleet of Autonomous Disinfection Robots to a U.S. School District
26.3.2021 16:15:00 EET | Business Wire | Press release
Blue Ocean Robotics, the manufacturer of the autonomous disinfecting robot UVD Robots equipped with UV-C light, has been selected by Gallup McKinley County Schools (GMCS) in New Mexico to supply 37 UVD Robots to the districts’ schools to help fight the Coronavirus and other infectious diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210326005133/en/
Students from GMCS’ Twin Lakes School participated in a naming contest for the robot to help with socialization and morale. The school’s robot will now be known as Mr. Fox. UVD Robots were originally developed to fight Hospital Acquired Infections (HAI’s) and are now deployed in more than 60 countries worldwide in the healthcare sector, the hospitality industry, office complexes and educational facilities, meeting new and heightened expectations for safety and cleanliness. (Photo: Business Wire)
“COVID has taken an extraordinary toll on our community. The safety of our students and staff, developing a plan to bring them all back to school as safely as possible is our primary concern,” said Gallup McKinley Superintendent Michael Hyatt. “We wanted a larger, longer-term disinfection solution, adding a layer of protection that would disinfect surfaces and the air in our buildings and help fight COVID, colds, flu and infectious diseases for years to come.”
GMCS covers a community with many rural areas facing infrastructure issues that make virtual learning a challenge, approximately 1,500 students have no internet at home. The district also educates many special education students who learn better in the classroom.
“Unlike stationary disinfection robots, the UVD Robot is a fully autonomous robot. It integrates UV-C light to disinfect against viruses and bacteria on surfaces and the air, killing 99.99 percent of microorganisms within approximately 10 minutes in every room it disinfects,” said Claus Risager, CEO, Blue Ocean Robotics.
“We selected UVD Robots after rigorous review of numerous disinfecting robots,” said Hyatt. “UVD Robots delivered on all of our requirements including technical excellence, maturity and track record, quality of deployment, technical support and maintenance, and overall value.”
“We are excited to announce, what we believe is the largest deployment of autonomous disinfection robots in any U.S. school district,” said Per Juul Nielsen, CEO, UVD Robots. “We are honored to work with GMCS to go beyond COVID, bringing hospital-grade disinfection to the school district.”
About
UVD Robots is part of one of the world's leading groups in development of service robots, Blue Ocean Robotics, that includes brands GoBe Robots and PTR Robots. Blue Ocean Robotics is headquartered in Denmark and was recently included on Fast Company’s Top 10 of ‘Most Innovative Robotics Companies 2021.’
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005133/en/
Contact information
Camilla Almind Knudsen, Blue Ocean Robotics
+45 61 10 02 74
cak@blue-ocean-robotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom